Article
Rheumatology
Mukanthu H. Nyirenda, Jagtar Singh Nijjar, Marina Frleta-Gilchrist, Derek S. Gilchrist, Duncan Porter, Stefan Siebert, Carl S. Goodyear, Iain B. McInnes
Summary: In this study, the effect of JAK inhibitors on cytokine-activated T cells and the production of cytokines and chemokines induced by T cell-macrophage interactions was investigated. The results showed that JAK inhibitors prevented T cell maturation and reduced the production of proinflammatory cytokines and chemokines by activated macrophages.
Article
Rheumatology
Hannah Bower, Thomas Frisell, Daniela di Giuseppe, Benedicte Delcoigne, Gerd-Marfie Ahlenius, Eva Baecklund, Katerina Chatzidionysiou, Nils Feltelius, Helena Forsblad-d'Elia, Alf Kastbom, Lars Klareskog, Elisabet Lindqvist, Ulf Lindstrom, Carl Turesson, Christopher Sjowall, Johan Askling
Summary: Patients with inflammatory joint diseases (IJDs) have an increased risk of serious COVID-19 outcomes, potentially due to medical conditions other than IJD itself. The COVID-19 pandemic has measurable effects on rheumatology care provision, which will require further assessment for future impact.
Article
Rheumatology
Farzin Khosrow-Khavar, Seoyoung C. Kim, Hemin Lee, Su Been Lee, Rishi J. Desai
Summary: The study did not find evidence of increased cardiovascular risk with tofacitinib in patients with RA in a real-world setting. However, tofacitinib was associated with an increased risk of cardiovascular outcomes, although statistically non-significant, in patients with RA with cardiovascular risk factors.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Rene Westhovens, William F. C. Rigby, Desiree van der Heijde, Daniel W. T. Ching, William Stohl, Jonathan Kay, Arvind Chopra, Beatrix Bartok, Franziska Matzkies, Zhaoyu Yin, Ying Guo, Chantal Tasset, John S. Sundy, Angelika Jahreis, Neelufar Mozaffarian, Osvaldo Daniel Messina, Robert B. M. Landewe, Tatsuya Atsumi, Gerd R. Burmester
Summary: The study showed that Filgotinib significantly improved symptoms and physical function in active RA patients treated in combination with MTX, while FIL200 monotherapy did not show a significant advantage in ACR20 response rate compared to MTX.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Rheumatology
Kevin L. Winthrop, Yoshiya Tanaka, Tsutomu Takeuchi, Alan Kivitz, Franziska Matzkies, Mark C. Genovese, Deyuan Jiang, Kun Chen, Beatrix Bartok, Angelika Jahreis, Robin Besuyen, Gerd R. Burmester, Jacques-Eric Gottenberg
Summary: In patients with moderately to severely active rheumatoid arthritis, the safety and tolerability of Filgotinib were good, with a lower incidence of infections in the Filgotinib 200 mg dose group compared to placebo during long-term treatment.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Lotte van Ouwerkerk, Patrick Verschueren, Maarten Boers, Paul Emery, Pascal Hendrik Pieter de Jong, Robert B. M. Landewe, Willem Lems, Josef S. Smolen, Tom W. J. Huizinga, Cornelia F. Allaart, Sytske Anne Bergstra
Summary: In patients with rheumatoid arthritis (RA), the use of glucocorticoids (GC) as bridging therapy resulted in a more rapid clinical improvement and fewer changes in medication, but similar long-term GC use compared with patients who did not receive bridging therapy.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Claire Daien, Marek Krogulec, Paul Gineste, Jean-Marc Steens, Laurence Desroys du Roure, Sophie Biguenet, Didier Scherrer, Julien Santo, Hartmut Ehrlich, Patrick Durez
Summary: This study evaluated the safety and efficacy of ABX464 in patients with moderate-to-severe active rheumatoid arthritis. The results showed that ABX464 at a 50 mg dose was safe, well tolerated, and showed promising efficacy. The 100 mg dose had a high dropout rate due to gastrointestinal adverse events.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Kevin Winthrop, Juan Ignacio Vargas, Edit Drescher, Conrado Garcia, Alan Friedman, Barbara Hendrickson, Yihan Li, Justin Klaff, Alan Kivitz
Summary: The study assessed the immunogenicity of PCV-13 vaccination in patients with rheumatoid arthritis. Results showed that approximately two-thirds of patients achieved a satisfactory immune response to PCV-13, despite receiving concomitant MTX treatment.
Article
Rheumatology
Sakir Ahmed, Pankti Mehta, Aby Paul, S. Anu, Somy Cherian, Veena Shenoy, Kaveri K. Nalianda, Sanjana Joseph, Anagha Poulose, Padmanabha Shenoy
Summary: This study assessed the incidence and risk factors for breakthrough COVID-19 infections in vaccinated patients with autoimmune rheumatic diseases (AIRDs) and found that the levels of antibodies against the receptor binding domain of spike protein were associated with susceptibility to such infections. Breakthrough infections occurred in 7.4% of patients and were associated with seronegativity following vaccination.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
David Moulin, Marie Millard, Mahdia Taieb, Chloe Michaudel, Anne Aucouturier, Antoine Lefevre, Luis G. Bermudez-Humaran, Philippe Langella, Youssouf Sereme, Kristell Wanherdrick, Preeti Gautam, Xavier Mariette, Philippe Dieude, Jacques-Eric Gottenberg, Jean-Yves Jouzeau, David Skurnik, Patrick Emond, Denis Mulleman, Jeremie Sellam, Harry Sokol
Summary: This study investigates the alterations in tryptophan metabolism in rheumatoid arthritis (RA) and their potential as therapeutic targets. The results show significant changes in Trp metabolite levels in RA patients compared to healthy controls, and these alterations are associated with disease severity and quality of life. The study also demonstrates the therapeutic potential of targeting the kynurenine pathway in RA.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Walter Reinisch, Wayne Hellstrom, Radboud J. E. M. Dolhain, Suresh Sikka, Rene Westhovens, Rajiv Mehta, Timothy Ritter, Ursula Seidler, Oleksandr Golovchenko, Vladimir Simanenkov, Olena Garmish, Slawomir Jeka, Radka Moravcova, Vijay Rajendran, Franck-Olivier Le Brun, Sarah Arterburn, Timothy R. Watkins, Robin Besuyen, Dirk Vanderschueren
Summary: The phase 2 MANTA and MANTA-RAy studies aimed to determine the impact of the oral Janus kinase 1 inhibitor filgotinib on semen parameters and sex hormones in men with inflammatory diseases. Results showed that once daily filgotinib 200 mg for 13 weeks had no measurable impact on semen parameters or sex hormones.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Joanna Kedra, Alexandre Lafourcade, Bernard Combe, Maxime Dougados, David Hajage, Bruno Fautrel
Summary: This study assessed the impact of disease-modifying antirheumatic drugs (DMARDs) on 10-year outcomes in patients with rheumatoid arthritis (RA) and found that early initiation of conventional synthetic DMARDs can reduce the risk of functional and structural outcomes.
Article
Rheumatology
Ara H. Dikranian, Miguel A. Gonzalez-Gay, Frank Wellborne, Jose Maria Alvaro-Gracia, Liza Takiya, Lori Stockert, Jerome Paulissen, Harry Shi, Svitlana Tatulych, Jeffrey R. Curtis
Summary: This post hoc analysis assessed the impact of baseline body mass index (BMI) on the efficacy of tofacitinib in treating rheumatoid arthritis. The results showed that tofacitinib demonstrated greater efficacy improvements compared to placebo in different BMI categories, and there was no consistent association between BMI and treatment outcomes.
Article
Rheumatology
Daniel Aletaha, Clifton O. Bingham, George Athanasios Karpouzas, Tsutomu Takeuchi, Carter Thorne, Androniki Bili, Prasheen Agarwal, Benjamin Hsu, Ravi Rao, Kurt Brown, Yoshiya Tanaka
Summary: Sirukumab, a human monoclonal antibody targeting IL-6, demonstrated consistent safety and efficacy in the long-term extension study, with reductions in RA symptoms and improvements in physical function sustained over time.
Article
Rheumatology
Benazir Saleem, Rebecca L. Ross, Lesley-Anne Bissell, Aamir Aslam, Kulveer Mankia, Laurence Duquenne, Diane Corsadden, Clive Carter, Pam Hughes, Fatima A. Nadat, Panji Mulipa, Mark Lobb, Brendan Clarke, Katie Mbara, Ruth Morton, Sophie Dibb, Rahaymin Chowdhury, Darren Newton, Alexandra Pike, Vishal Kakkar, Sinisia Savic, Francesco DelGaldo, Paul Emery
Summary: This study assessed the antibody and T cell responses to SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on disease-modifying antirheumatic drugs (DMARDs). The results showed reduced vaccine responses in RA patients, especially with certain DMARDs. However, subsequent vaccinations improved the immune response in some patients.
Article
Cell Biology
Kathryne E. Young, Stephanie Flaherty, Kaitlyn M. Woodman, Neelam Sharma-Walia, Joseph M. Reynolds
JOURNAL OF LEUKOCYTE BIOLOGY
(2017)
Article
Cell Biology
Kathryne E. Marks, Stephanie Flaherty, Kristen M. Patterson, Matthew Stratton, Gustavo J. Martinez, Joseph M. Reynolds
Summary: The study shows that activation of TLR2 increases the pathogenicity and migratory capacity of Th17 cells, comparable to IL-23. RNA sequencing revealed differential expression of genes associated with Th17 pathogenicity through the TLR2 pathway, including Ipcef1.
Review
Immunology
Kathryne E. Marks, Deepak A. Rao
Summary: Pathologic T cell-B cell interactions play a crucial role in autoimmune diseases. Tph cells, a unique subset of T cells, have been identified in autoantibody-associated diseases, providing both B cell help and the ability to migrate to inflamed peripheral tissues. Understanding and tracking Tph cells are crucial for studying the pathogenesis and therapeutic strategies of autoimmune diseases.
IMMUNOLOGICAL REVIEWS
(2022)
Meeting Abstract
Rheumatology
S. Tedeschi, J. Stratton, J. Ellrodt, M. G. Whelan, K. Hayashi, K. Yoshida, L. Chen, I. Adejoorin, K. E. Marks, A. H. Jonsson, D. Rao, D. Solomon
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Takanori Sasaki, Sabrina Bracero, Joshua Keegan, Lin Chen, Ye Cao, Emma Stevens, Yujie Qu, Guoxing Wang, Jennifer Nguyen, Jeffrey A. Sparks, V. Michael Holers, Stephen E. Alves, James A. Lederer, Karen H. Costenbader, Deepak A. Rao
Summary: The study investigated the immune cell profiles of patients with SLE, finding expansion of helper T cell subsets and Ki-67+ proliferating immune cell subsets in early SLE patients. Unique immunologic features evolved over time in early SLE patients, with some cell populations showing increased levels and others showing decreased levels over the course of 1 year.
ARTHRITIS & RHEUMATOLOGY
(2022)
Article
Rheumatology
Sara K. Tedeschi, Daniel H. Solomon, Yuezhou Chen, Jack Ellrodt, Mary Grace Whelan, Jacklyn Stratton, Keigo Hayashi, Noah Benjamin Whiteman, Lin Chen, Ifeoluwakiisi Adejoorin, Kathryne E. Marks, Emma Gomez-Rivas, Deepak A. Rao, Helena Jonsson, Duane R. Wesemann
Summary: This study compared humoral and cell-mediated immunity before and after a third dose of mRNA COVID vaccine in rheumatoid arthritis (RA) subjects. The results showed that although disease-modifying anti-rheumatic drugs (DMARDs) significantly increased the virus-specific IgG levels in RA patients, fewer than two-thirds achieved a humoral response like healthy controls. There was no correlation between humoral and cellular changes.
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2023)
Article
Immunology
Runci Wang, Anvita Singaraju, Kathryne E. Marks, Lorien Shakib, Garrett Dunlap, Ifeoluwakiisi Adejoorin, Stinne R. Greisen, Lin Chen, Aidan K. Tirpack, Carlos Aude, Miriam R. Fein, Derrick J. Todd, Lindsey MacFarlane, Susan M. Goodman, Edward F. DiCarlo, Elena M. Massarotti, Jeffrey A. Sparks, A. Helena Jonsson, Michael B. Brenner, Michael A. Postow, Karmela K. Chan, Anne R. Bass, Laura T. Donlin, Deepak A. Rao
Summary: Immune checkpoint inhibitor (ICI) therapies, such as anti-PD-1 antibodies, can induce autoimmune conditions in some cancer patients. This study found that patients with ICI-induced arthritis had clonal expansion of activated effector CD8 T cells in their joints and blood, which displayed an elevated interferon signature. These findings suggest that ICI therapy directly targets CD8 T cells and induces a distinct autoimmune pathology in patients with ICI-arthritis.
SCIENCE IMMUNOLOGY
(2023)
Article
Rheumatology
Kelly D. O'Neill, Kathryne E. Marks, Pamela S. Sinicrope, Cynthia S. Crowson, Dana Symons, Elena Myasoedova, John M. Davis
Summary: The study found that the majority of rheumatoid arthritis patients do not discuss treatment goals with their providers, but such discussions are associated with improvements in disease activity and treatment satisfaction.
ACR OPEN RHEUMATOLOGY
(2021)
Review
Immunology
Kathryne E. Marks, Kaylin Cho, Courtney Stickling, Joseph M. Reynolds
Summary: TLR signaling is critical for immune recognition, particularly in activating and maturing cells of innate immunity. TLR2 heterodimerizes with TLR1 or TLR6 to recognize bacterial lipopeptides and danger molecules, promoting immune cell activation for infection defense. However, overactive inflammation due to inappropriate TLR2 signaling may have detrimental effects in sterile inflammation and autoimmune diseases.
